The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized controlled phase III trial comparing thoracoscopic esophagectomy and open esophagectomy for thoracic esophageal cancer: JCOG1409 (MONET trial).
 
Hiroya Takeuchi
Honoraria - Abbott Japan; Bristol-Myers Squibb Japan; Daiichi Sankyo/Astra Zeneca; EA Pharma; Hisamitsu Pharmaceutical; Intuitive Surgical; Johnson & Johnson/MedTech; Kaken Pharmaceutical; Medicon; Medtronic; Miyarisan pharmaceutical; MSD K.K; Nichiiko K.K.; Ono Pharmaceutical; Otsuka; Otsuka; Taiho Pharmaceutical; Tsumura & Co.
Research Funding - Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Johnson & Johnson/MedTech; Kaken Pharmaceutical; Kyowa Hakko Kirin K. K.; Lilly Japan; Otsuka; Taiho Pharmaceutical
 
Masahiko Ando
Research Funding - Kyowa Kirin (Inst)
 
Yasuhiro Tsubosa
No Relationships to Disclose
 
Hirotoshi Kikuchi
No Relationships to Disclose
 
Hirofumi Kawakubo
No Relationships to Disclose
 
Kazuhiro Noma
No Relationships to Disclose
 
Masaki Ueno
No Relationships to Disclose
 
Takahiro Tsushima
Honoraria - Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
 
Takeo Bamba
No Relationships to Disclose
 
Takeo Fujita
No Relationships to Disclose
 
Yoichi Hamai
No Relationships to Disclose
 
Tomokazu Kakishita
No Relationships to Disclose
 
Hiroyuki Daiko
No Relationships to Disclose
 
Kazuo Koyanagi
No Relationships to Disclose
 
Satoru Matsuda
No Relationships to Disclose
 
Ken Kato
Honoraria - BMS; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - Bayer; BeiGene; MSD; Oncolys BioPharma; Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Chugai Pharma (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Keita Sasaki
No Relationships to Disclose
 
Ryosuke Kita
No Relationships to Disclose
 
Ryunosuke Machida
No Relationships to Disclose
 
Yuko Kitagawa
Honoraria - Asahi Kasei; ASKA Pharmaceutical Co., Ltd.; AstraZeneca Japan; Bristol-Myers Squibb K.K.; Chugai Foundation for Innovative Drug Discovery Science; Chugai Pharma; DAIICHI SANKYO COMPANY, LIMITED; EA Pharma; Ethicon; Intuitive Surgical; Kaken Pharmaceutical; Miyarisan pharmaceutical; MSD K.K.; Nippon Covidien; Nippon Kayaku; Olympus; Ono Pharmaceutical; Otsuka; Shionogi; Smith & Nephew; Sysmex; Taiho Pharmaceutical; Toray Industries
Consulting or Advisory Role - Bristol-Myers Squibb K.K.; Ono Pharmaceutical
Research Funding - Asahi Kasei (Inst); Chugai Pharma (Inst); Eisai (Inst); Kaken Pharmaceutical (Inst); Kowa (Inst); Kyouwa Hakkou Kirin Co., Ltd. (Inst); Nippon Covidien (Inst); Otsuka (Inst); Otsuka (Inst); Sumitomo Pharma Co., Ltd. (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Teijin Pharma (Inst); TSUMURA & CO. (Inst)